Home > Addressing important therapeutic questions in squamous NSCLC
Thoracic Oncology

Addressing important therapeutic questions in squamous NSCLC

Published Online: September 2nd 2015

D. Planchard provides an expert perspective for results and toxicity data in trials performed in advanced squamous NSCLC and reported at ASCO 2015. In particular, he elaborates results of nedaplatin plus docetaxel in advanced or relapsed setting, afatinib vs erlotinib in second-line treatment, and nivolumab vs docetaxel in previously treated advanced or metastatic squamous NSCLC.

Related Videos In Thoracic Oncology
  • Journal articles and more to your inbox


    Get the latest clinical insights from touchRESPIRATORY

    Sign me up!
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowlinkmenumore_dots padlock person play-colourAsset 1podcastprinter search share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrow